secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACURA PHARMACEUTICALS, INC (—)
CIK:        0000786947
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001104659-25-020108
Event type: debt
Sentiment:  negative
Materiality: 0.95
Item codes: 1.01, 2.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acura extends loan maturity and NDA deadline to May 31; warns of possible shutdown without new financing
--------------------------------------------------------------------------------

- Received $325k in new loans from AD Pharma in Feb 2025; total principal $7.49M at 5.25% interest.
- Maturity of secured note and warrant expiration extended from Feb 28 to May 31, 2025.
- LTX-03 NDA acceptance deadline extended to May 31, 2025; AD Pharma may terminate and take IP if not accepted.
- Without additional financing by mid-March 2025, company will scale back operations, furlough employees, or terminate operations.
- AD Pharma (controlled by John Schutte) owns ~65% of Acura's outstanding common stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/786947/000110465925020108/0001104659-25-020108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/786947/000110465925020108/tm254408d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-020108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer